{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:50:07Z","timestamp":1791910207606,"version":"4.3.4"},"reference-count":210,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.phrs.2022.106181","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T22:57:38Z","timestamp":1647298658000},"page":"106181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Anti-rheumatic drug-induced hepatitis B virus reactivation and preventive strategies for hepatocellular carcinoma"],"prefix":"10.1016","volume":"178","author":[{"given":"Qiao","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunming","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Polaris Observatory","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"10100","key":"10.1016\/j.phrs.2022.106181_bib2","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.","volume":"390","author":"Disease","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.phrs.2022.106181_bib3","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1473-3099(16)30204-3","article-title":"Requirements for global elimination of hepatitis B: a modelling study","volume":"16","author":"Nayagam","year":"2016","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2022.106181_bib5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev-med-080119-103356","article-title":"New therapeutics for hepatitis B: the road to cure","volume":"72","author":"Naggie","year":"2021","journal-title":"Annu Rev. Med."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/jmbi.2000.4481","article-title":"Structural organization of the hepatitis B virus minichromosome","volume":"307","author":"Bock","year":"2001","journal-title":"J. Mol. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106181_bib7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2009.05.022","article-title":"Control of cccDNA function in hepatitis B virus infection","volume":"51","author":"Levrero","year":"2009","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.phrs.2022.106181_bib8","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1136\/gutjnl-2019-319637","article-title":"Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription","volume":"69","author":"Salerno","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2022.106181_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/v9040075","article-title":"HBV DNA integration: molecular mechanisms and clinical implications","volume":"9","author":"Tu","year":"2017","journal-title":"Viruses"},{"issue":"5415","key":"10.1016\/j.phrs.2022.106181_bib10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","article-title":"Viral clearance without destruction of infected cells during acute HBV infection","volume":"284","author":"Guidotti","year":"1999","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1128\/JCM.36.2.531-538.1998","article-title":"Amplification of full-length hepatitis B virus genomes from samples from patients with low levels of viremia: frequency and functional consequences of PCR-introduced mutations","volume":"36","author":"Gunther","year":"1998","journal-title":"J. Clin. Microbiol."},{"issue":"Pt 4","key":"10.1016\/j.phrs.2022.106181_bib12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1099\/vir.0.83468-0","article-title":"Effect of basal core promoter and pre-core mutations on hepatitis B virus replication","volume":"89","author":"Jammeh","year":"2008","journal-title":"J. Gen. Virol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106181_bib13","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.gastro.2006.01.001","article-title":"Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones","volume":"130","author":"Pollicino","year":"2006","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.phrs.2022.106181_bib14","doi-asserted-by":"crossref","first-page":"9392","DOI":"10.1128\/jvi.71.12.9392-9399.1997","article-title":"Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus","volume":"71","author":"Moraleda","year":"1997","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.phrs.2022.106181_bib15","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cgh.2013.01.026","article-title":"Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency","volume":"11","author":"Wong","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"43","key":"10.1016\/j.phrs.2022.106181_bib16","doi-asserted-by":"crossref","first-page":"5447","DOI":"10.3748\/wjg.v16.i43.5447","article-title":"Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients","volume":"16","author":"Brost","year":"2010","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/hep.27609","article-title":"Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?","volume":"61","author":"Di Bisceglie","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.phrs.2022.106181_bib18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrclinonc.2012.1","article-title":"Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer","volume":"9","author":"Torres","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.phrs.2022.106181_bib19","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","article-title":"Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study","volume":"32","author":"Seto","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2022.106181_bib20","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2012.05.009","article-title":"Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors","volume":"57","author":"Huang","year":"2012","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.antiviral.2011.10.022","article-title":"Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection","volume":"93","author":"Svicher","year":"2012","journal-title":"Antivir. Res"},{"issue":"5 Suppl","key":"10.1016\/j.phrs.2022.106181_bib22","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1002\/hep.22945","article-title":"Reactivation of hepatitis B","volume":"49","author":"Hoofnagle","year":"2009","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.phrs.2022.106181_bib23","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.phrs.2022.106181_bib24","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/nsr\/nwu038","article-title":"The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma","volume":"1","author":"Yang","year":"2014","journal-title":"Natl. Sci. Rev."},{"issue":"5 Suppl 1","key":"10.1016\/j.phrs.2022.106181_bib25","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2022.106181_bib26","first-page":"S6","article-title":"Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment","volume":"76 Suppl 3","author":"Sherman","year":"2009","journal-title":"Cleve Clin. J. Med."},{"key":"10.1016\/j.phrs.2022.106181_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-S4-05","article-title":"The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective","volume":"15 Suppl 4","author":"Venook","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2022.106181_bib28","doi-asserted-by":"crossref","first-page":"12992","DOI":"10.1038\/ncomms12992","article-title":"Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma","volume":"7","author":"Zhao","year":"2016","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.phrs.2022.106181_bib29","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/ng.2295","article-title":"Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma","volume":"44","author":"Sung","year":"2012","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.phrs.2022.106181_bib30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ccr.2014.01.030","article-title":"Viral-human chimeric transcript predisposes risk to liver cancer development and progression","volume":"25","author":"Lau","year":"2014","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.phrs.2022.106181_bib31","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1172\/JCI63455","article-title":"MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis","volume":"122","author":"Tsai","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2022.106181_bib32","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S1386-6532(05)80014-9","article-title":"HBV induced carcinogenesis","volume":"34 Suppl 1","author":"Cougot","year":"2005","journal-title":"J. Clin. Virol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.virol.2012.01.021","article-title":"Hepatitis B virus regulatory HBx protein binding to DDB1 is required but is not sufficient for maximal HBV replication","volume":"426","author":"Hodgson","year":"2012","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.phrs.2022.106181_bib34","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.celrep.2016.08.026","article-title":"Hepatitis B virus X protein promotes degradation of SMC5\/6 to enhance HBV replication","volume":"16","author":"Murphy","year":"2016","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib35","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.febslet.2005.12.034","article-title":"The X protein of hepatitis B virus binds to the F box protein Skp2 and inhibits the ubiquitination and proteasomal degradation of c-Myc","volume":"580","author":"Kalra","year":"2006","journal-title":"FEBS Lett."},{"issue":"1\u20132","key":"10.1016\/j.phrs.2022.106181_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11010-013-1769-5","article-title":"Hepatitis B virus X (HBx) play an anti-apoptosis role in hepatic progenitor cells by activating Wnt\/\u03b2-catenin pathway","volume":"383","author":"Shen","year":"2013","journal-title":"Mol. Cell Biochem"},{"issue":"15","key":"10.1016\/j.phrs.2022.106181_bib37","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1128\/MCB.23.15.5282-5292.2003","article-title":"Involvement of Crm1 in hepatitis B virus X protein-induced aberrant centriole replication and abnormal mitotic spindles","volume":"23","author":"Forgues","year":"2003","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2022.106181_bib38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.20517\/2394-5079.2016.05","article-title":"Hepatitis B virus molecular biology and pathogenesis","volume":"2","author":"Lamontagne","year":"2016","journal-title":"Hepatoma Res."},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib39","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jhep.2014.04.041","article-title":"Hepatitis B virus PreS\/S gene variants: pathobiology and clinical implications","volume":"61","author":"Pollicino","year":"2014","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.phrs.2022.106181_bib40","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1349-7006.2006.00235.x","article-title":"Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis","volume":"97","author":"Wang","year":"2006","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib41","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/carcin\/bgr296","article-title":"Aberrant cyclin A expression and centrosome overduplication induced by hepatitis B virus pre-S2 mutants and its implication in hepatocarcinogenesis","volume":"33","author":"Wang","year":"2012","journal-title":"Carcinogenesis"},{"issue":"8 Pt 1","key":"10.1016\/j.phrs.2022.106181_bib42","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1440-1746.2008.05348.x","article-title":"Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection","volume":"23","author":"Su","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106181_bib43","article-title":"HBsAg inhibits the translocation of JTB into mitochondria in HepG2 cells and potentially plays a role in HCC progression","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"issue":"47","key":"10.1016\/j.phrs.2022.106181_bib44","doi-asserted-by":"crossref","first-page":"19975","DOI":"10.1073\/pnas.0908365106","article-title":"Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function","volume":"106","author":"Belloni","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib45","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jhep.2008.10.019","article-title":"Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A","volume":"50","author":"Zheng","year":"2009","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.phrs.2022.106181_bib46","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1128\/JVI.02574-12","article-title":"Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription","volume":"87","author":"Benhenda","year":"2013","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106181_bib47","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jhep.2015.06.023","article-title":"HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase","volume":"63","author":"Riviere","year":"2015","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.phrs.2022.106181_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004343","article-title":"The Tudor domain protein Spindlin1 is involved in intrinsic antiviral defense against incoming hepatitis B Virus and herpes simplex virus type 1","volume":"10","author":"Ducroux","year":"2014","journal-title":"PLoS Pathog."},{"issue":"10","key":"10.1016\/j.phrs.2022.106181_bib49","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/gut.2003.033324","article-title":"Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma","volume":"53","author":"Chan","year":"2004","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.phrs.2022.106181_bib50","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/jvh.12134","article-title":"Combinations of eight key mutations in the X\/preC region and genomic activity of hepatitis B virus are associated with hepatocellular carcinoma","volume":"21","author":"Park","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.phrs.2022.106181_bib51","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1440-1746.2010.06541.x","article-title":"The clinical implications of hepatitis B virus genotype: recent advances","volume":"26 Suppl 1","author":"Lin","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.phrs.2022.106181_bib52","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1128\/JVI.72.8.6785-6795.1998","article-title":"Naturally occurring mutations define a novel function of the hepatitis B virus core promoter in core protein expression","volume":"72","author":"Baumert","year":"1998","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib53","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1128\/JVI.73.2.1239-1244.1999","article-title":"Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation","volume":"73","author":"Li","year":"1999","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib54","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jmv.23895","article-title":"HBV genotype C strains with spontaneous YMDD mutations may be a risk factor for hepatocellular carcinoma","volume":"86","author":"Yang","year":"2014","journal-title":"J. Med. Virol."},{"issue":"1 Suppl","key":"10.1016\/j.phrs.2022.106181_bib55","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2022.106181_bib56","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/JHC.S307962","article-title":"The mechanisms of HBV-induced hepatocellular carcinoma","volume":"8","author":"Jiang","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"4","key":"10.1016\/j.phrs.2022.106181_bib57","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.patbio.2009.11.001","article-title":"Pathogenesis of hepatitis B virus infection","volume":"58","author":"Chisari","year":"2010","journal-title":"Pathol. Biol."},{"issue":"8","key":"10.1016\/j.phrs.2022.106181_bib58","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib59","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1053\/j.gastro.2018.10.032","article-title":"Targeting innate and adaptive immune responses to cure chronic HBV infection","volume":"156","author":"Gehring","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2022.106181_bib60","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3389\/fimmu.2018.00219","article-title":"Hepatitis B virus-specific CD8+ T cells maintain functional exhaustion after antigen reexposure in an acute activation immune environment","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117458","article-title":"Impaired function of CD4+ T follicular helper (Tfh) cells associated with hepatocellular carcinoma progression","volume":"10","author":"Jia","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2022.106181_bib62","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.3389\/fimmu.2019.02048","article-title":"HBV-induced immune imbalance in the development of HCC","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol."},{"issue":"12","key":"10.1016\/j.phrs.2022.106181_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001227","article-title":"Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection","volume":"6","author":"Peppa","year":"2010","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib64","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tem.2017.10.010","article-title":"Therapeutic mechanisms of glucocorticoids","volume":"29","author":"Vandewalle","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.phrs.2022.106181_bib65","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(24)00526-3","article-title":"The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis","volume":"24","author":"Hench","year":"1949","journal-title":"Proc. Staff Meet. Mayo Clin."},{"issue":"3","key":"10.1016\/j.phrs.2022.106181_bib66","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-020-0371-y","article-title":"Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases","volume":"16","author":"Hardy","year":"2020","journal-title":"Nat. Rev. Rheuma"},{"issue":"8","key":"10.1016\/j.phrs.2022.106181_bib67","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/ard.2005.043257","article-title":"Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies","volume":"65","author":"Calabrese","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2022.106181_bib68","doi-asserted-by":"crossref","first-page":"2931402","DOI":"10.1155\/2018\/2931402","article-title":"Recent advances in HBV reactivation research","volume":"2018","author":"Guo","year":"2018","journal-title":"Biomed. Res. Int."},{"issue":"4","key":"10.1016\/j.phrs.2022.106181_bib69","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41577-020-00464-0","article-title":"Glucocorticoids in T cell development, differentiation and function","volume":"21","author":"Taves","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib70","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/0042-6822(88)90127-4","article-title":"The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer","volume":"167","author":"Tur-Kaspa","year":"1988","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib71","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1073\/pnas.83.6.1627","article-title":"Hepatitis B virus DNA contains a glucocorticoid-responsive element","volume":"83","author":"Tur-Kaspa","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib72","article-title":"Immunosuppressive drugs modulate the replication of hepatitis B virus (HBV) in a hydrodynamic injection mouse model","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.phrs.2022.106181_bib73","first-page":"566","article-title":"Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment","volume":"215","author":"Chen","year":"2017","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib74","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/liv.13953","article-title":"Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B","volume":"39","author":"Wong","year":"2019","journal-title":"Liver Int."},{"issue":"4","key":"10.1016\/j.phrs.2022.106181_bib75","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10067-013-2450-9","article-title":"Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review","volume":"33","author":"Xuan","year":"2014","journal-title":"Clin. Rheuma"},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib76","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcv.2004.02.013","article-title":"Hepatic failure due to fibrosing cholestatic hepatitis in a patient with pre-surface mutant hepatitis B virus and mixed connective tissue disease treated with prednisolone and chloroquine","volume":"31","author":"Zanati","year":"2004","journal-title":"J. Clin. Virol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib77","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2169\/internalmedicine.37.519","article-title":"Antibody to hepatitis B e positive hepatitis induced by withdrawal of steroid therapy for polymyositis: response to interferon-alpha and cyclosporin A","volume":"37","author":"Nakanishi","year":"1998","journal-title":"Intern. Med."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib78","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3899\/jrheum.100692","article-title":"Reactivation of hepatitis B virus after steroid treatment in rheumatic diseases","volume":"38","author":"Cheng","year":"2011","journal-title":"J. Rheuma"},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib79","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3350\/cmh.2012.18.2.225","article-title":"A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier","volume":"18","author":"Bae","year":"2012","journal-title":"Clin. Mol. Hepatol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib80","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/0961203317711009","article-title":"Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study","volume":"27","author":"Lin","year":"2018","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.phrs.2022.106181_bib81","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1440-1843.2010.01798.x","article-title":"Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids","volume":"15","author":"Kim","year":"2010","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib82","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.phrs.2022.106181_bib83","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/RHU.0000000000000434","article-title":"Safety of corticosteroid treatment in rheumatologic patients with markers of hepatitis B viral infection: pilot evaluation study","volume":"22","author":"Braun-Moscovici","year":"2016","journal-title":"J. Clin. Rheuma"},{"issue":"3","key":"10.1016\/j.phrs.2022.106181_bib84","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2133.2007.08058.x","article-title":"Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy","volume":"157","author":"Yang","year":"2007","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib85","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11096-017-0584-6","article-title":"The prevalence and risk factors of hepatitis B flares in chronic hepatitis B patients receiving glucocorticoid pulse therapy","volume":"40","author":"Lin","year":"2018","journal-title":"Int. J. Clin. Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib86","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.phrs.2022.106181_bib87","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature","volume":"68","author":"Visser","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.phrs.2022.106181_bib88","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/1751-2980.12184","article-title":"A review of methotrexate-associated hepatotoxicity","volume":"15","author":"Bath","year":"2014","journal-title":"J. Dig. Dis."},{"issue":"3","key":"10.1016\/j.phrs.2022.106181_bib89","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jbspin.2018.07.004","article-title":"Methotrexate mechanism in treatment of rheumatoid arthritis","volume":"86","author":"Friedman","year":"2019","journal-title":"Jt. Bone Spine"},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib90","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3109\/s10165-011-0458-z","article-title":"Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and\/or nonbiological disease-modifying antirheumatic drugs","volume":"21","author":"Mori","year":"2011","journal-title":"Mod. Rheuma"},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib91","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12072-014-9597-6","article-title":"Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients","volume":"9","author":"Laohapand","year":"2015","journal-title":"Hepatol. Int."},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib92","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2016-209973","article-title":"Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan","volume":"76","author":"Fukuda","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.phrs.2022.106181_bib93","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.phrs.2022.106181_bib94","doi-asserted-by":"crossref","first-page":"d1417","DOI":"10.1136\/bmj.d1417","article-title":"Life threatening myelotoxicity secondary to azathioprine in a patient with atopic eczema and normal thiopurine methyltransferase activity","volume":"342","author":"Wee","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib95","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hep.1840220107","article-title":"Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro","volume":"22","author":"McMillan","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2022.106181_bib96","unstructured":"Padda, I.S. and A. Goyal, Leflunomide, in StatPearls. 2021: Treasure Island (FL)."},{"key":"10.1016\/j.phrs.2022.106181_bib97","first-page":"20","article-title":"Mechanism of action of leflunomide in rheumatoid arthritis","volume":"53","author":"Fox","year":"1998","journal-title":"J. Rheuma Suppl."},{"issue":"3","key":"10.1016\/j.phrs.2022.106181_bib98","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/clim.1999.4777","article-title":"Mechanism of action for leflunomide in rheumatoid arthritis","volume":"93","author":"Fox","year":"1999","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib99","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/14656566.2.1.125","article-title":"Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis","volume":"2","author":"Alldred","year":"2001","journal-title":"Expert Opin. Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12985-020-01339-5","article-title":"Mitomycin, 5-fluorouracil, leflunomide, and mycophenolic acid directly promote hepatitis B virus replication and expression in vitro","volume":"17","author":"Ruan","year":"2020","journal-title":"Virol. J."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib101","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/hep.25602","article-title":"The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replication in vitro","volume":"56","author":"Hoppe-Seyler","year":"2012","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib102","first-page":"320","article-title":"Clinical outcomes of low-dose leflunomide for rheumatoid arthritis complicated with Hepatitis B virus carriage and safety observation","volume":"31","author":"Ming-Xu","year":"2015","journal-title":"Pak. J. Med. Sci."},{"key":"10.1016\/j.phrs.2022.106181_bib103","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/1471-2474-15-449","article-title":"Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice","volume":"15","author":"Mo","year":"2014","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.phrs.2022.106181_bib104","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20912646","article-title":"Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations","volume":"12","author":"Koutsianas","year":"2020","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.phrs.2022.106181_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2020-001171","article-title":"HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?","volume":"6","author":"Gremese","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.phrs.2022.106181_bib106","doi-asserted-by":"crossref","unstructured":"Burmester, G.R., et al., Managing rheumatic and musculoskeletal diseases - past, present and future. Nat Rev Rheumatol, 2017. 13(7): p. 443\u2013448.","DOI":"10.1038\/nrrheum.2017.95"},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib107","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/0886022X.2017.1399908","article-title":"Sulfasalazine induces mitochondrial dysfunction and renal injury","volume":"39","author":"Niknahad","year":"2017","journal-title":"Ren. Fail"},{"issue":"5","key":"10.1016\/j.phrs.2022.106181_bib108","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1172\/JCI992","article-title":"Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B","volume":"101","author":"Wahl","year":"1998","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.phrs.2022.106181_bib109","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/sj.bjp.0702937","article-title":"Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine","volume":"128","author":"Liptay","year":"1999","journal-title":"Br. J. Pharm."},{"issue":"5","key":"10.1016\/j.phrs.2022.106181_bib110","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1567-5769(01)00186-2","article-title":"Regulation of human B cell function by sulfasalazine and its metabolites","volume":"2","author":"Hirohata","year":"2002","journal-title":"Int Immunopharmacol."},{"issue":"12","key":"10.1016\/j.phrs.2022.106181_bib111","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1002\/art.20637","article-title":"Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand","volume":"50","author":"Lee","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.phrs.2022.106181_bib112","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/1529-0131(200009)43:9<1941::AID-ANR4>3.0.CO;2-O","article-title":"The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis","volume":"43","author":"Rodenburg","year":"2000","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib113","doi-asserted-by":"crossref","first-page":"15307","DOI":"10.1038\/s41598-017-15338-0","article-title":"Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP","volume":"7","author":"Donkers","year":"2017","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.phrs.2022.106181_bib114","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2169\/internalmedicine.55.5425","article-title":"Hepatitis B virus reactivation following salazosulfapyridine monotherapy in a patient with rheumatoid arthritis","volume":"55","author":"Akashi","year":"2016","journal-title":"Intern. Med."},{"issue":"7","key":"10.1016\/j.phrs.2022.106181_bib115","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1073\/pnas.75.7.3327","article-title":"Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents","volume":"75","author":"Ohkuma","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.phrs.2022.106181_bib116","first-page":"803","article-title":"Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells","volume":"20","author":"Sperber","year":"1993","journal-title":"J. Rheuma"},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/archderm.1967.01610010007001","article-title":"Immunologic concepts of light reactions in lupus erythematosus and polymorphous light eruptions. I. The mechanism of action of hydroxychloroquine","volume":"96","author":"Lester","year":"1967","journal-title":"Arch. Dermatol."},{"issue":"11","key":"10.1016\/j.phrs.2022.106181_bib118","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1182\/blood.V95.11.3460","article-title":"Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties","volume":"95","author":"Goldman","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.phrs.2022.106181_bib119","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ncprheum0292","article-title":"Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling","volume":"2","author":"Kyburz","year":"2006","journal-title":"Nat. Clin. Pr. Rheuma"},{"issue":"5","key":"10.1016\/j.phrs.2022.106181_bib120","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1191\/0961203306lu2299oa","article-title":"Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients","volume":"15","author":"Wozniacka","year":"2006","journal-title":"Lupus"},{"issue":"2 Suppl","key":"10.1016\/j.phrs.2022.106181_bib121","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1097\/01.tp.0000186390.10150.66","article-title":"Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection","volume":"80","author":"Allison","year":"2005","journal-title":"Transplantation"},{"issue":"2\u20133","key":"10.1016\/j.phrs.2022.106181_bib122","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"issue":"3","key":"10.1016\/j.phrs.2022.106181_bib123","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2893.1999.00163.x","article-title":"Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro","volume":"6","author":"Gong","year":"1999","journal-title":"J. Viral Hepat."},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib124","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0166-3542(00)00121-2","article-title":"Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus","volume":"48","author":"Ying","year":"2000","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.phrs.2022.106181_bib125","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.reuma.2014.09.003","article-title":"Severe infections in patients with autoimmune diseases treated with cyclophosphamide","volume":"11","author":"Cavallasca","year":"2015","journal-title":"Reum. Clin."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib126","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.revmed.2011.07.013","article-title":"[Management of the risk of hepatitis B virus reactivation in patients receiving immunosuppressive and immunomodulatory agents in internal medicine: data from the REACTI-B survey and proposal for a management algorithm]","volume":"33","author":"Terrier","year":"2012","journal-title":"Rev. Med Interne"},{"issue":"9","key":"10.1016\/j.phrs.2022.106181_bib127","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/acr.21990","article-title":"Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases","volume":"65","author":"Droz","year":"2013","journal-title":"Arthritis Care Res."},{"issue":"11","key":"10.1016\/j.phrs.2022.106181_bib128","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1007\/s10067-018-4295-8","article-title":"Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs-a single-center analysis of 2054 patients","volume":"37","author":"Schwaneck","year":"2018","journal-title":"Clin. Rheuma"},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib129","first-page":"111","article-title":"[Effects of ciclosporin and tacrolimus on replication of hepatitis B virus in vitro: a comparative study]","volume":"86","author":"Xia","year":"2006","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib130","first-page":"18","article-title":"Inhibitory effect of cyclosporine A on hepatitis B virus replication in vitro and its possible mechanisms","volume":"4","author":"Xia","year":"2005","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"issue":"7","key":"10.1016\/j.phrs.2022.106181_bib131","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/ndt\/5.7.525","article-title":"Viral hepatitis in HBsAg-positive renal transplant patients treated with cyclosporin and steroids","volume":"5","author":"Sandrini","year":"1990","journal-title":"Nephrol. Dial. Transpl."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib132","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/s10165-010-0337-z","article-title":"Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients","volume":"21","author":"Urata","year":"2011","journal-title":"Mod. Rheuma"},{"key":"10.1016\/j.phrs.2022.106181_bib133","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/941767","article-title":"Prevalence of past and reactivated viral infections and efficacy of cyclosporine A as monotherapy or in combination in patients with psoriatic arthritis--synergy study: a longitudinal observational study","volume":"2014","author":"Colombo","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.phrs.2022.106181_bib134","first-page":"1","volume":"9","author":"Colombo","year":"2016","journal-title":"Clin. Cosmet. Invest. Dermatol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib135","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","article-title":"Mode of action of tacrolimus (FK506): molecular and cellular mechanisms","volume":"17","author":"Thomson","year":"1995","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.phrs.2022.106181_bib136","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.1993.tb17137.x","article-title":"The mechanism of action of FK-506 and cyclosporin A","volume":"696","author":"Wiederrecht","year":"1993","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib137","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0002-9394(14)73645-1","article-title":"A clinical trial of FK506 in refractory uveitis","volume":"115","author":"Mochizuki","year":"1993","journal-title":"Am. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106181_bib138","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.26982","article-title":"Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)","volume":"59","author":"Watashi","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2022.106181_bib139","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"issue":"3","key":"10.1016\/j.phrs.2022.106181_bib140","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1034\/j.1399-3062.2003.00021.x","article-title":"Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation","volume":"5","author":"Duhart","year":"2003","journal-title":"Transpl. Infect. Dis."},{"issue":"4","key":"10.1016\/j.phrs.2022.106181_bib141","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3109\/s10165-012-0709-7","article-title":"Association of hepatitis B with antirheumatic drugs: a case-control study","volume":"23","author":"Oshima","year":"2013","journal-title":"Mod. Rheuma"},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib142","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib143","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation","volume":"177","author":"Moreira","year":"1993","journal-title":"J. Exp. Med"},{"issue":"4","key":"10.1016\/j.phrs.2022.106181_bib144","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1445-5994.2008.01653.x","article-title":"Hepatitis B reactivation after thalidomide","volume":"38","author":"Grigg","year":"2008","journal-title":"Intern. Med. J."},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11894-019-0669-6","article-title":"Managing risks with biologics","volume":"21","author":"Click","year":"2019","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.phrs.2022.106181_bib146","unstructured":"V. Gerriets.\u00a0et al. Tumor necrosis factor inhibitors StatPearls 2021 Treasure Island FL."},{"issue":"11","key":"10.1016\/j.phrs.2022.106181_bib147","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection--natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"6176","key":"10.1016\/j.phrs.2022.106181_bib148","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib149","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases","volume":"90","author":"Perez-Alvarez","year":"2011","journal-title":"Medicine"},{"key":"10.1016\/j.phrs.2022.106181_bib150","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/926836","article-title":"HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-alpha) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis","volume":"2014","author":"Cantini","year":"2014","journal-title":"Int. J. Rheuma"},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib151","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acr.20130","article-title":"Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative\/anti-hepatitis B core antigen positive) with rheumatic diseases","volume":"62","author":"Caporali","year":"2010","journal-title":"Arthritis Care Res."},{"issue":"7","key":"10.1016\/j.phrs.2022.106181_bib152","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1136\/ard.2009.127233","article-title":"Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection","volume":"69","author":"Vassilopoulos","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.phrs.2022.106181_bib153","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2004.040675","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis","volume":"53","author":"Esteve","year":"2004","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.phrs.2022.106181_bib154","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1136\/ard.2010.148783","article-title":"Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy","volume":"70","author":"Lan","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.phrs.2022.106181_bib155","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.3899\/jrheum.081324","article-title":"Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy","volume":"36","author":"Chung","year":"2009","journal-title":"J. Rheuma"},{"issue":"12","key":"10.1016\/j.phrs.2022.106181_bib156","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.3748\/wjg.v17.i12.1531","article-title":"Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy","volume":"17","author":"Manzano-Alonso","year":"2011","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106181_bib157","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/cmi.2015.25","article-title":"Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients","volume":"12","author":"Xu","year":"2015","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmii.2017.10.002","article-title":"Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: a narrative review","volume":"52","author":"Chen","year":"2019","journal-title":"J. Microbiol Immunol. Infect."},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib159","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/annrheumdis-2012-202088","article-title":"Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection","volume":"72","author":"Mitroulis","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.phrs.2022.106181_bib160","first-page":"831","article-title":"Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for rheumatoid arthritis","volume":"35","author":"Tien","year":"2017","journal-title":"Clin. Exp. Rheuma"},{"issue":"5","key":"10.1016\/j.phrs.2022.106181_bib161","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3899\/jrheum.151105","article-title":"Low risk of hepatitis B virus reactivation in HBsAg-negative\/Anti-HBc-positive carriers receiving rituximab for rheumatoid arthritis: a retrospective multicenter Italian study","volume":"43","author":"Varisco","year":"2016","journal-title":"J. Rheuma"},{"issue":"3","key":"10.1016\/j.phrs.2022.106181_bib162","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-009-0806-7","article-title":"Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients","volume":"89","author":"Pei","year":"2010","journal-title":"Ann. Hematol."},{"issue":"16","key":"10.1016\/j.phrs.2022.106181_bib163","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2013.281115","article-title":"FDA: increased HBV reactivation risk with ofatumumab or rituximab","volume":"310","author":"Mitka","year":"2013","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.phrs.2022.106181_bib164","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib165","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/blood.V97.1.198","article-title":"Synthesis and release of B-lymphocyte stimulator from myeloid cells","volume":"97","author":"Nardelli","year":"2001","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.phrs.2022.106181_bib166","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1084\/jem.192.7.953","article-title":"Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response","volume":"192","author":"Do","year":"2000","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib167","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1073\/pnas.050552997","article-title":"A B-cell receptor-specific selection step governs immature to mature B cell differentiation","volume":"97","author":"Levine","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib168","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat. Rev. Rheuma"},{"key":"10.1016\/j.phrs.2022.106181_bib169","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaut.2019.04.016","article-title":"Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells","volume":"101","author":"Lorenzetti","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.phrs.2022.106181_bib170","unstructured":"Abatacept, in LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)."},{"issue":"11","key":"10.1016\/j.phrs.2022.106181_bib171","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","article-title":"Abatacept: a review in rheumatoid arthritis","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib172","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/rheumatology\/ket221","article-title":"Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection","volume":"53","author":"Fanouriakis","year":"2014","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.phrs.2022.106181_bib173","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/acr.21654","article-title":"Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B","volume":"64","author":"Kim","year":"2012","journal-title":"Arthritis Care Res."},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib174","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/acr.22786","article-title":"Safety of abatacept in rheumatoid arthritis with serologic evidence of past or present hepatitis B virus infection","volume":"68","author":"Padovan","year":"2016","journal-title":"Arthritis Care Res."},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib175","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.idc.2020.02.009","article-title":"Hepatitis B virus reactivation potentiated by biologics","volume":"34","author":"Ogawa","year":"2020","journal-title":"Infect. Dis. Clin. North Am."},{"issue":"12","key":"10.1016\/j.phrs.2022.106181_bib176","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrrheum.2014.127","article-title":"IL-6 biology: implications for clinical targeting in rheumatic disease","volume":"10","author":"Calabrese","year":"2014","journal-title":"Nat. Rev. Rheuma"},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib177","doi-asserted-by":"crossref","first-page":"R187","DOI":"10.1186\/ar2099","article-title":"The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis","volume":"8","author":"Bondeson","year":"2006","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2022.106181_bib178","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/1759720X10378372","article-title":"The role of interleukin 6 in the pathophysiology of rheumatoid arthritis","volume":"2","author":"Srirangan","year":"2010","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"issue":"17","key":"10.1016\/j.phrs.2022.106181_bib179","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: a review in rheumatoid arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.phrs.2022.106181_bib180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142599","article-title":"IL6 inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome","volume":"10","author":"Palumbo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2022.106181_bib181","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.virol.2015.02.026","article-title":"Interleukin 6 inhibits HBV entry through NTCP down regulation","volume":"481","author":"Bouezzedine","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.phrs.2022.106181_bib182","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1423-0127-16-41","article-title":"HBV replication is significantly reduced by IL-6","volume":"16","author":"Kuo","year":"2009","journal-title":"J. Biomed. Sci."},{"issue":"7","key":"10.1016\/j.phrs.2022.106181_bib183","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/1756-185X.13010","article-title":"Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation","volume":"20","author":"Chen","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.phrs.2022.106181_bib184","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/rheumatology\/ken384","article-title":"Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B","volume":"47","author":"Nagashima","year":"2008","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.phrs.2022.106181_bib185","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.3899\/jrheum.110289","article-title":"Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen-negative cases","volume":"38","author":"Kato","year":"2011","journal-title":"J. Rheuma"},{"issue":"5","key":"10.1016\/j.phrs.2022.106181_bib186","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/1756-185X.12359","article-title":"Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs","volume":"19","author":"Nakamura","year":"2016","journal-title":"Int. J. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib187","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/hep.27716","article-title":"Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection","volume":"62","author":"Barone","year":"2015","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib188","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.23226","article-title":"Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection","volume":"50","author":"Hosel","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.phrs.2022.106181_bib189","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2016-209831","article-title":"A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2022.106181_bib190","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000479475","article-title":"Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others","volume":"53","author":"Puig","year":"2018","journal-title":"Curr. Probl. Dermatol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106181_bib191","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjd.12120","article-title":"Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient","volume":"168","author":"Koskinas","year":"2013","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106181_bib192","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1172\/JCI28508","article-title":"The IL-23\/IL-17 axis in inflammation","volume":"116","author":"Iwakura","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2022.106181_bib193","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3389\/fimmu.2017.01195","article-title":"Immunity and fibrogenesis: the role of Th17\/IL-17 Axis in HBV and HCV-induced chronic hepatitis and progression to cirrhosis","volume":"8","author":"Paquissi","year":"2017","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib194","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/j.1478-3231.2012.02764.x","article-title":"Pivotal roles of the interleukin-23\/T helper 17 cell axis in hepatitis B","volume":"32","author":"Huang","year":"2012","journal-title":"Liver Int."},{"issue":"8","key":"10.1016\/j.phrs.2022.106181_bib195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023330","article-title":"Licensing virus-specific T cells to secrete the neutrophil attracting chemokine CXCL-8 during hepatitis B virus infection","volume":"6","author":"Gehring","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib196","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12461","article-title":"The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C","volume":"169","author":"Chiu","year":"2013","journal-title":"Br. J. Dermatol."},{"issue":"9","key":"10.1016\/j.phrs.2022.106181_bib197","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40261-018-0671-z","article-title":"Risk of hepatitis B reactivation in patients with psoriasis on ustekinumab","volume":"38","author":"Ting","year":"2018","journal-title":"Clin. Drug Invest."},{"issue":"9","key":"10.1016\/j.phrs.2022.106181_bib198","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE extension study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"9","key":"10.1016\/j.phrs.2022.106181_bib199","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2340\/00015555-2989","article-title":"Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study","volume":"98","author":"Chiu","year":"2018","journal-title":"Acta Derm. Venereol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106181_bib200","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/00003246-200205000-00015","article-title":"Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients","volume":"30","author":"Ma","year":"2002","journal-title":"Crit. Care Med"},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib201","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard.2004.033662","article-title":"Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice","volume":"65","author":"den Broeder","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib202","first-page":"318","article-title":"The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin. Exp. Rheuma"},{"issue":"8","key":"10.1016\/j.phrs.2022.106181_bib203","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1089\/1079990041689665","article-title":"Induction and regulation of IFNs during viral infections","volume":"24","author":"Malmgaard","year":"2004","journal-title":"J. Interferon Cytokine Res"},{"issue":"5","key":"10.1016\/j.phrs.2022.106181_bib204","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/annrheumdis-2017-211322","article-title":"Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study","volume":"77","author":"Chen","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2022.106181_bib205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2019-001095","article-title":"Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis","volume":"6","author":"Harigai","year":"2020","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.phrs.2022.106181_bib206","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1517\/14740338.2015.1031743","article-title":"Drug safety evaluation of apremilast for treating psoriatic arthritis","volume":"14","author":"Busa","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"issue":"28","key":"10.1016\/j.phrs.2022.106181_bib207","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.2174\/0929867324666170530093902","article-title":"Phosphodiesterase 4 inhibitors in immune-mediated diseases: mode of action, clinical applications, current and future perspectives","volume":"24","author":"Sakkas","year":"2017","journal-title":"Curr. Med Chem."},{"issue":"1","key":"10.1016\/j.phrs.2022.106181_bib208","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1124\/jpet.113.204933","article-title":"Rolipram attenuates bile duct ligation-induced liver injury in rats: a potential pathogenic role of PDE4","volume":"347","author":"Gobejishvili","year":"2013","journal-title":"J. Pharm. Exp. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2022.106181_bib209","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3350\/cmh.2016.0024","article-title":"Prevention of hepatitis B reactivation in the setting of immunosuppression","volume":"22","author":"Pattullo","year":"2016","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.phrs.2022.106181_bib210","unstructured":"Nucleoside Analogues, in LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012: Bethesda (MD)."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822001268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822001268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:35:36Z","timestamp":1760913336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822001268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":210,"alternative-id":["S1043661822001268"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106181","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-rheumatic drug-induced hepatitis B virus reactivation and preventive strategies for hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106181"}}